Rosemary-Based Rosmagain Formulation for Hair Regrowth: 2025 RCT Research Summary
This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.
Original research published in Cureus (PMC), 2025
Rosemary-Based Rosmagain Formulation for Hair Regrowth
Study conclusion
Double-blind, three-arm, placebo-controlled RCT found that a rosemary-based formulation called Rosmagain significantly improved hair growth, thickness, density, and scalp health compared to control. This was a more rigorous design than most supplement studies, but tested a proprietary formulation rather than pure rosemary oil.
Strength of evidence
This was a double-blind three-arm randomised controlled trial — a stronger design than most supplement studies. The score is limited because this is a single trial testing a proprietary branded formulation, the study was published in Cureus (a broad open-access journal), and the formulation studied is not commercially available as a mass-market product.
Who it applies to
Who was studied
Adults with hair loss. Double-blind, three arms. Rosmagain formulation compared against placebo/control.
Who was NOT studied
People using pure rosemary oil. People with severe hair loss. The formulation includes rosemary alongside other components.
What to look for when shopping
Rosmagain is a specific proprietary formulation — not the same as generic rosemary oil products available on the market. No rosemary product is FDA-approved for hair loss.
What research cannot help you decide
Whether generic rosemary oil products available in stores would produce similar results. How Rosmagain compares to FDA-approved treatments.
Key findings
- The Rosmagain rosemary-based formulation significantly improved hair growth, thickness, and density vs control
- Scalp health measures also improved significantly
- This was a double-blind placebo-controlled RCT — stronger than many supplement studies
- The formulation studied is proprietary — results may not apply to generic rosemary oil products
- No rosemary product is FDA-approved for hair loss
What they did
A double-blind randomised placebo-controlled trial with three arms. Participants were assigned to the Rosmagain rosemary-based formulation, another active comparison, or placebo/control. Hair growth, thickness, density, and scalp health were measured at baseline and follow-up.
What they found
| Comparison | Result | Significant? |
|---|---|---|
| Rosmagain vs control — hair growth | Significant improvement | Yes |
| Rosmagain vs control — hair thickness and density | Significant improvement | Yes |
| Rosmagain vs control — scalp health | Significant improvement | Yes |
What this study does not show
- 1.Whether results apply to generic rosemary oil products sold in stores.
- 2.How the formulation compares to FDA-approved treatments like minoxidil.
- 3.Long-term effects beyond the trial period.
Limitations
- 1.Single trial of a proprietary formulation
- 2.Published in Cureus — a broad open-access journal with less stringent editorial selectivity
- 3.Results may not generalise to generic rosemary oil products
- 4.No rosemary product is FDA-approved for hair loss
Who funded it
No funding source declared. No conflicts of interest reported.
Used in these articles
Links added as fact-checks and articles citing this study are published.